Drug Profile
Quinupristin/dalfopristin
Alternative Names: RP 57669/RP54476; RP 59500; SynercidLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Antibacterials; Streptogramins
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Enterococcal infections; Gram-positive infections; Nosocomial pneumonia; Skin and soft tissue infections
Most Recent Events
- 01 Mar 2011 King Pharmaceuticals has been acquired and merged into Pfizer
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis